With no single headline event setting the tone, Arrowhead Pharmaceuticals (ARWR) is drawing attention as investors weigh its recent share performance against current financial metrics and the breadth ...
Arrowhead Pharmaceuticals has surged over 240% in six months, driven by major partnerships and its RNAi drug pipeline. Recent catalysts include a $200M Novartis deal, $300M from Sarepta, and the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results